Caesars Entertainment misses Q2 earnings expectations, shares edge lower
In a recent transaction, DeLyle W. Bloomquist, President and CEO of Rayonier Advanced Materials Inc. (NYSE:RYAM), acquired shares valued at approximately $249,879. This insider purchase comes as the stock trades near its 52-week low of $3.45, having declined over 54% in the past six months. According to InvestingPro data, management has been actively buying back shares, showing strong insider confidence despite recent market challenges. The acquisition, which took place on May 16, involved the purchase of 63,291 shares of common stock at a weighted average price of $3.9481 per share. This transaction increased Bloomquist’s total direct holdings to 486,024 shares. The purchase was executed through multiple trades with prices ranging from $3.945 to $4.00 per share. With the company’s market capitalization at $289 million and current trading levels suggesting the stock is fairly valued based on InvestingPro’s Fair Value analysis, investors can access comprehensive insider trading patterns and 10+ additional ProTips through the detailed Pro Research Report.
In other recent news, Rayonier Advanced Materials reported its first-quarter 2025 earnings, which fell short of expectations. The company announced an earnings per share of -$0.49, a significant miss compared to the forecasted $0.04. Revenue also came in below projections at $356 million, compared to the anticipated $395.75 million. This underperformance has led to a reduction in the company’s full-year adjusted EBITDA guidance to a range of $175-185 million. Additionally, Rayonier Advanced Materials held its Annual Meeting of Stockholders, where three director nominees were elected to terms expiring in 2028, and the compensation of named executive officers was approved on an advisory basis. However, stockholders did not approve amendments to declassify the board of directors and eliminate supermajority voting provisions. The selection of Grant Thornton LLP as the company’s independent registered public accounting firm for 2025 was ratified. Despite these challenges, the company continues to pursue its biomaterials strategy and explore alternative markets to mitigate tariff impacts on its cellulose commodities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.